LBA20 Primary results from ASCENT-03: A randomized phase III study of sacituzumab govitecan (SG) vs chemotherapy (chemo) in patients (pts) with previously untreated advanced triple-negative breast cancer (TNBC) who are unable to receive PD-(L)1 inhibitors (PD-[L]1i)
Year: 2025
Type: conference-abstract
Source: Annals of Oncology
Institutions: Hospital Universitario de Torrejón, MedSIR (Spain), Universidad Europea de Madrid, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, Ziekenhuis aan de Stroom, Latin American Cooperative Oncology Group (LACOG), University of Washington, Fred Hutch Cancer Center, German Cancer Research Center, University Hospital Heidelberg, Yonsei Cancer Hospital, National Hospital Organization Kyushu Cancer Center, Magee-Womens Hospital, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Samsung Medical Center, Sungkyunkwan University, Chinese Academy of Medical Sciences & Peking Union Medical College, Cancer Hospital of Chinese Academy of Medical Sciences, Universidade de São Paulo, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Università Cattolica del Sacro Cuore, Agostino Gemelli University Polyclinic, Istituti di Ricovero e Cura a Carattere Scientifico, Gilead Sciences (United States), Harvard University, Dana-Farber Cancer Institute
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: bronze
Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Gilead Sciences, American Society of Clinical Oncology, Celgene, Helsinn, Exelixis, Jazz Pharmaceuticals, National Comprehensive Cancer Network, Clovis Oncology, Mylan, Mersana Therapeutics, Relay Therapeutics, MacroGenics, Seagen, Natera, Eisai, Sociedad Española de Oncología Médica, Genentech, Chugai Pharmaceutical, Eli Lilly Japan, Gilead UK and Ireland Corporate Contributions, Daiichi Sankyo Europe
OpenAlex ID: W4416391875